PPIDT00436
Drug Information
| Name | Mosunetuzumab |
|---|---|
| Sequence | EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB15434 |
| Type | biotech |
| Indication | Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.[L42230,L44562] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Concentrate | Intravenous |
1 mg/1mL
|
| Concentrate | Intravenous |
30 mg/30mL
|
| Injection, solution, concentrate | Intravenous |
1 mg
|
| Injection, solution, concentrate | Intravenous |
30 mg
|
| Injection, solution, concentrate | Intravenous |
1 mg/ml
|